替比夫定治疗失代偿期乙肝肝硬化的临床分析

A Clinical Analysis of The Effect of Telbivudine on Hepatitis B-related Cirrhosis in Decompensatory Stage

目的：探讨替比夫定治疗失代偿期乙肝肝硬化的临床疗效.方法：抽取2012年2月-2014年2月某院接诊的76例失代偿乙肝肝硬化患者为研究对象,根据抽签法随机抽取38例患者采用替比夫定的治疗,作为观察组;38例患者采用常规治疗,作为对照组.观察两组患者的肝功能指标、肝纤维化指标以及药物不良反应的情况.结果：治疗后观察组的ALT、TBIL指标明显低于对照组,ALB指标明显高于对照组,组间比较差异具有统计学意义（P 〈0.05）;治疗后观察组的肝纤维化指标CIV、PIIINP、LN 以及HA均明显低于对照组,组间差异具有统计学意义（P 〈0.05）;观察组总不良反应发生率5.26%明显低于对照组的26.32%,两组差异具有统计学意义（χ^2=6.333,P 〈0.05）.结论：替比夫定治疗失代偿期乙肝肝硬化具有更好的治疗效果,能有效改善患者的肝功能并抑制病情的发展,具有-定的临床意义.

Objective:To investigate the clinical effect of telbivudine on Hepatitis B-related cirrhosis in de-compensatory stage.Methods:Sample 76 patients with Hepatitis B-related cirrhosis within decompensatory stage received in our hospital during the period from February 2012 to February 2014 as the research object, select 38 patients according to the random sampling method as the observation group and treat them with tel-bivudine and the other 38 patients were defined as the control group and received conventional treatment.Ob-serve the indexes of liver function ,the indexes of hepatic fibrosis and adverse drug reaction.Results:After treatment,the index of ALT and TBIL in observation group were obviously lower than that in control group, and the index of ALB was obviously higher than that in control group,the differences between the 2 groups were statistically significant(P<0.05).After treatment,CIV、PIIINP、LN and HA in observation group were all lower than that in control group ,the differences between the 2 groups were statistically significant(P<0.05).In observation group,the overall occurrence rate of adverse reaction was 5.26% ,which was lower than that in control group(26.32%),the differences between the 2 groups were statistically significant(χ2=6.333,P<0.05).Conclusion:It is more effective to treat patients with Hepatitis B-related cirrhosis within de-compensatory stage,it would effectively improve patients'liver function and inhibit the development of the situation,it is of some clinical significance.